Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

Oncol Res Treat 2016;39: DOI: /

Advertisements

SIOP-E HR-MBL Hungarian Proposal

Harrison CN et al. Proc ASH 2015;Abstract 59.

Figure 4 Progression-free survival, according to treatment group

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 1 Male infertility and assisted reproduction globally

Nat. Rev. Urol. doi: /nrurol

Figure 1 The UMBRELLA SIOP-RTSG 2016 protocol logo

Figure 5 Schematic illustration of different clinical trial designs

Figure 3 Semantic model of the active surveillance (AS) timeline

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Representative images from a right radical

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Urol. doi: /nrurol

Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk.

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Schema for the phase II Randomized Observation versus

Figure 1 The development process of the Asian

Nat. Rev. Urol. doi: /nrurol

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Volume 19, Issue 8, Pages (August 2018)

Figure 3 Algorithm for the determination of the clinical

Nat. Rev. Urol. doi: /nrurol

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 6 Image sequence demonstrating coronal cuts on MRI

Volume 386, Issue 9999, Pages (September 2015)

Nat. Rev. Urol. doi: /nrurol

Figure 3 Template for standard pelvic lymphadenectomy

Nat. Rev. Cardiol. doi: /nrcardio

Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients Years of Age with Secondary Acute.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves for overall survival (OS) probability.

Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small- Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of.

Supplementary Figure 2 Shiota et al.

• Kaplan-Meier analyses of (A) overall survival (OS) of the whole cohort (n=173), (B) OS from time of diagnosis of high-risk melanoma among those who remained.

Figure 3 Overall survival, according to treatment group

Enrollment and Outcomes

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Nat. Rev. Urol. doi: /nrurol

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

American Journal of Kidney Diseases

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Figure 2 Kaplan-Meier survival graphs for 10-year risks of overall and post-90-day recurrent ischemic stroke (IS) and death Kaplan-Meier survival graphs.

Stavros V. Konstantinides et al. JACC 2017;69:

Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation Celia Grosskreutz,

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients Barbara S. van der Meij,

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Kaplan-Meier event-free survival from ipsilateral stroke for patients with near occlusion, pooled data from the NASCET and ECST. The 3-year intention-to-treat.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2017.163 Figure 3 Post hoc analysis of data from patients with stage II or III, intermediate-risk, nonstromal, nonepithelial Wilms tumour in the SIOP−2001 randomized controlled trial Figure 3 | Post hoc analysis of data from patients with stage II or III, intermediate-risk, nonstromal, nonepithelial Wilms tumour in the SIOP−2001 randomized controlled trial. Association of tumour volume and treatment with a | event-free survival (EFS) and b | overall survival (OS). Kaplan Meier curves. AV-2, actinomycin D, vincristine (27 weeks); AVD, actinomycin D, vincristine and doxorubicin. van den Heuvel-Eibrink, M. M. et al. (2017) Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol Nat. Rev. Urol. doi:10.1038/nrurol.2017.163